Aran Frank Labrijn

USPTO Granted Patents = 36 (Patent Applications = 34)

CIPO Patents = 5 (Patent Applications = 11)

EPO Patents = 22 (Patent Applications = 43)

Average Co-Inventor Count = 7.9

ph-index = 13

Forward Citations = 470(Granted Patents)

Location History:

Amsterdam, NL (2009 - 2018)
Nigtevecht, NL (2014 - 2024)
Utrecht, NL (2015 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),

2. 12338289 - Antibody variant combinations and uses thereof (2025-06-24),

3. 12247065 - Method for producing a controlled mixture of two or more different antibodies (2025-03-11),

4. 12049512 - Antibody variants and uses thereof (2024-07-30),

5. 11932693 - Monoclonal antibodies directed against programmed death-1 protein and their use in medicine (2024-03-19),

6. 11866514 - Heterodimeric antibody Fc-containing proteins and methods for production thereof (2024-01-09),

7. 11613575 - Humanized or chimeric CD3 antibodies (2023-03-28),

8. 11578141 - Bispecific antibodies against HER2 and CD3 (2023-02-14),

9. 11512140 - Monoclonal antibodies against c-Met (2022-11-29),

10. 11492371 - Production of heterodimeric proteins (2022-11-08),

11. 11485796 - Inert format (2022-11-01),

12. 11180572 - Dimeric protein with triple mutations (2021-11-23),

13. 11091553 - Monoclonal antibodies against HER2 (2021-08-17),

14. 11046771 - Monoclonal antibodies against HER2 (2021-06-29),

15. 10906991 - Bispecific antibodies and methods for production thereof (2021-02-02),

Title: Inventor Spotlight: Aran Frank Labrijn

Introduction: Aran Frank Labrijn, a prolific inventor hailing from Nigtevecht, NL, is a distinguished figure in the field of biotechnology with an impressive portfolio of 32 patents to his name. His groundbreaking work in the development of monoclonal antibodies and heterodimeric antibody-Fc-containing proteins has significantly advanced the field of medicine, particularly in the realm of immunotherapy for cancer treatment.

Latest Patents: One of Labrijn's latest patents revolves around monoclonal antibodies directed against the programmed death-1 (PD-1) protein, showcasing his expertise in harnessing the power of the immune system for therapeutic purposes. These antibodies have been strategically engineered to modulate the immune checkpoint pathway, offering novel avenues for enhancing anti-cancer immune responses and improving patient outcomes.

Career Highlights: Throughout his illustrious career, Labrijn has made significant contributions while working with esteemed companies such as Genmab A/S and Roche Palo Alto LLC. His innovative spirit and dedication to advancing biotechnological solutions have paved the way for transformative developments in the field of medicine, setting new standards for patient care and treatment efficacy.

Collaborations: Labrijn's collaborative efforts with esteemed colleagues like Paul Parren and Janine Schuurman have been instrumental in driving forward key research initiatives and translating novel scientific discoveries into practical applications. By fostering a culture of innovation and interdisciplinary collaboration, Labrijn has forged invaluable partnerships that have propelled his work to new heights.

Conclusion: In conclusion, Aran Frank Labrijn stands as a beacon of innovation in the realm of biotechnology, with a remarkable track record of patents and pioneering contributions to the field of antibody-based therapeutics. His relentless pursuit of excellence and unwavering commitment to advancing medical science underscore his status as a visionary inventor whose work continues to shape the future of healthcare and biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.